This strain colonizes at tumor cells and releases nano-antibodies targeting programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) using a stabilized lysing release mechanism. This evidence concerns the gene CTLA4 and neoplasm.